Clinical evolution of substance use disorder patients during treatment with quetiapine: A 12-week, open-label, naturalistic trial

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 18, 2010, Pages 2947-2951

  Rizkallah, Élie ^a,b   Stip, Emmanuel ^a   Zhornitsky, Simon ^a   Pampoulova, Tania ^a,b   Gendron, Alain ^c   Rompré, Pierre Paul ^a   Chiasson, Jean Pierre ^b   Potvin, Stéphane ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Atypical antipsychotic; Detoxification; Psychiatric symptom; Quetiapine; Substance use disorders

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABIS; COCAINE; QUETIAPINE;

ADJUVANT THERAPY; ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTHRALGIA; ARTICLE; BECK DEPRESSION INVENTORY; BLURRED VISION; BODY WEIGHT; BORDERLINE STATE; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; CANNABIS ADDICTION; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONSTIPATION; DEPRESSION; DETOXIFICATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG FORMULATION; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; HYPERSALIVATION; MALE; MENTAL DISEASE; OPEN STUDY; PATIENT COMPLIANCE; PERSONALITY DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUBSTANCE ABUSE; SYMPTOM; TREATMENT OUTCOME; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 78649269595     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.524927     Document Type: Article

References (29)

1. Zhornitsky S, Rizkallah E, Pampoulova T, et al. Antipsychotics for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol 2010;30:417-24
2. Green AI, Noordsy DL, Brunette MF, et al. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 2008;34:61-71
3. Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol 2007;27:344-51
4. Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol 2004;24:532-5
5. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 2004;29:452-7
6. Pinkofsky HB, Hahn AM, Campbell FA, et al. Reduction of opioid-withdrawal symptoms with quetiapine. J Clin Psychiatry 2005;66:1285-8
7. Kennedy A, Wood AE, Saxon AJ, et al. Quetiapine for the treatment of cocaine dependence: an open-label trial. J Clin Psychopharmacol 2008;28:221-4
8. Mauri MC, Volonteri LS, Fiorentini A, et al. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007;8:2207-13
9. West R, Gossop M. Overview: a comparison of withdrawal symptoms from different drug classes. Addiction 1994;89:1483-9
10. Baune BT. New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatr Dis Treat 2008;4:1181-91
11. Bogart GT, Chavez B. Safety and efficacy of quetiapine in bipolar depression. Ann Pharmacother 2009;43:1848-56
12. Substance Abuse and Mental Health Services Administration (SAMHSA). Polydrug admission: 2002. The Drug and Alcohol Services Information System Report 2005
13. Kenna GA, Nielsen DM, Mello P, et al. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 2007;21:213-37
14. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: Litten JARZ, editor, Measuring alcohol consumption: psychosocial and biological methods. Humana Press, Totowa, NJ; 1992; 41-72
15. Drake RE, Osher FC, Noordsy DL, et al. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull 1990;16:57-67
16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
17. Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-8
18. Levin FR, Evans SM, Coomaraswammy S, et al. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 1998;24:343-60
19. Zhornitsky S, Stip E, Pampoulova T, et al. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in non-abusing patients with schizophrenia. Mov Disord 2010;25:2188-94
20. Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. Psychological Corporation, San Antonio, TX; 1996
21. Atasoy N, Erdogan A, Yalug I, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1255-60
22. Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006;22:1277-85
23. Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008;23:417-24
24. Holbrook AM, Crowther R, Lotter A, et al. Diagnosis and management of acute alcohol withdrawal. CMAJ 1999;160:675-80
25. Miller NS. Pharmacotherapy in alcoholism. J Addict Dis 1995;14:23-46
26. Oulis P, Konstantakopoulos G. Pregabalin in the treatment of alcohol and benzodiazepines dependence. CNS Neurosci Ther 2010;16:45-50
27. Keller R, Mongini F. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 2002;23:233-5
28. Nakajima M, Terao T, Iwata N, et al. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry 2005;38:17-19
29. Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009;42:29-34